Defining the goal
Treatment aims in particular to limit progression. Its value cannot be judged from a single photograph: progress, tolerability and follow-up matter. It does not replace assessment of the cause or a long-term plan.
Discussing adverse effects
Sexual and psychiatric adverse effects can occur. Sexual symptoms have been reported to persist after discontinuation. Medical history, possible symptoms and patient information need discussion before prescribing.
European safety information
In 2025, the European Medicines Agency confirmed suicidal thoughts as an adverse effect of finasteride tablets, with unknown frequency. A person taking 1 mg finasteride for hair loss who develops mood changes should stop treatment and seek prompt medical advice. Sexual symptoms should also be reported to the prescriber.
An individual decision
The decision is neither automatic nor the same for everyone. It depends on understanding benefits and risks. Formulation, indication and conditions of use must be checked for the product and country concerned. New symptoms should lead to reassessment.
Recent scientific publications
Selected references consulted on 18 November 2026. Studies concern specific populations and protocols; they do not predict individual outcomes.
52-week retrospective study
Effectiveness and Safety of Topical Finasteride for Male Androgenetic Alopecia: Real World Data
Piraccini BM et al. International Journal of Dermatology, October 2026 (online March 2026). · PMID 41874081
This study of 146 men reports improvement with topical finasteride. No control group and selected participants limit interpretation; no observed systemic adverse effects does not mean no risk.
Retrospective observational study
Long-term effectiveness and safety of topical finasteride 0.25% monotherapy in male androgenetic alopecia: a 52-week real-world retrospective study
Gallo G et al. Clinical and Experimental Dermatology, August 2026 (online publication). · PMID 42546161
One-year follow-up of 123 men using photography and trichoscopy. Observed improvements add real-world evidence, but the study does not directly compare topical with oral finasteride.
Randomised placebo-controlled trial
Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study
Chinese Medical Journal, April 2026 (online March 2025). · PMID 40090937
A 24-week trial in 270 men supporting an effect on hair growth. Findings concern the tested formulation and population, with limited follow-up; the study was industry funded.